Pushpakom S, Kolamunnage-Dona R, Taylor C, et al. - Researchers here examined if insulin resistance in human immunodeficiency virus (HIV)–positive individuals on antiretrovirals could be reduced using telmisartan. They conducted a multicenter, randomized, open-label, dose-ranging controlled trial randomizing 377 HIV–positive individuals on antiretroviral therapy to either no intervention (control) or 20, 40, or 80 mg telmisartan once daily. Per outcomes, telmisartan did not show any significant effect on the homeostasis model assessment of insulin resistance, however, it led to marginal improvements in revised Quantitative Insulin Sensitivity Check Index and plasma hs-CRP and a reduction in liver fat content.